Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 13:2018:3629031.
doi: 10.1155/2018/3629031. eCollection 2018.

Adrenal Insufficiency in Cystic Fibrosis: A Rare Phenomenon?

Sébastien Préville-Ratelle  1 , Adèle Coriati  2 , Aurélie Ménard  2 , Isabelle Bourdeau  3   4 , François Tremblay  1   4 , Yves Berthiaume  1   2   4
Affiliations

Adrenal Insufficiency in Cystic Fibrosis: A Rare Phenomenon?

Sébastien Préville-Ratelle et al. Can Respir J. .

Abstract

Background: The prevalence of adrenal insufficiency (AI) in cystic fibrosis (CF) is unknown. The frequent use of glucocorticoids (inhaled or systemic) may induce the long-term suppression of the hypothalamic-pituitary-adrenal axis.

Methods: We reviewed the results of adrenocorticotropic hormone (ACTH) stimulation tests done over a 10-year period to evaluate adrenal function in 69 CF patients of the CHUM CF clinic. Clinical characteristics of AI patients were compared to adrenal-sufficient (AS) patients.

Results: AI was confirmed in 33 of the 69 CF patients. A higher rate of dysglycemia (P=0.022) and of Aspergillus positive culture (P=0.006) was observed in AI patients compared to AS patients. Weight, CFTR genotype, and pulmonary function were comparable between AI and AS patients. The use of systemic corticosteroids (SC) prior to the diagnosis of AI was observed in 42.4% of patients. Compared to AI patients without SC, SC-treated AI patients were older and had a higher rate of allergic bronchopulmonary aspergillosis.

Conclusion: This study is the first to systematically examine the presence of AI in the largest cohort of CF patients studied to date with a prevalence of 8%. Patients treated with corticosteroids and those colonized with Aspergillus have a greater risk of AI.

PubMed Disclaimer

References

    1. Guerrero Perez F., Marengo A. P., Villabona Artero C. The unresolved riddle of glucocorticoid withdrawal. Journal of Endocrinological Investigation. 2017;40(11):1175–1181. doi: 10.1007/s40618-017-0691-1. - DOI - PubMed
    1. Agha A., Tomlinson J. W., Clark P. M., Holder G., Stewart P. M. The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitary-adrenal axis. Journal of Clinical Endocrinology and Metabolism. 2006;91(1):43–47. doi: 10.1210/jc.2005-1131. - DOI - PubMed
    1. Wlodarczyk J. H., Gibson P. G., Caeser M. Impact of inhaled corticosteroids on cortisol suppression in adults with asthma: a quantitative review. Annals of Allergy, Asthma & Immunology. 2008;100(1):23–30. doi: 10.1016/S1081-1206(10)60400-0. - DOI - PubMed
    1. Balfour-Lynn I. M., Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database of Systematic Reviews. 2014;(10):p. CD001915. doi: 10.1002/14651858.CD001915.pub4. - DOI - PubMed
    1. Parmar J. S., Howell T., Kelly J., Bilton D. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax. 2002;57(8):749–750. doi: 10.1136/thorax.57.8.749. - DOI - PMC - PubMed

Substances